Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01665-4/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esc25&_hsenc=p2ANqtz-9uM0WfbK5IKsEb8qD0oFP5vNKTO9CCIlLufX8nsCqekk_39qVibm0x3meZ1GJLjiCRSGfkUOAhmAEhwVcC4MUlupdbYg&_hsmi=378460064&utm_content=378460064&utm_source=hs_email